- Home
- HNRG vs OLMA Comparison
HNRG vs OLMA Comparison
Compare HNRG & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- OLMA
- Stock Information
- Founded
- HNRG 1949
- OLMA 2006
- Country
- HNRG United States
- OLMA United States
- Employees
- HNRG N/A
- OLMA N/A
- Industry
- HNRG Coal Mining
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- HNRG Energy
- OLMA Health Care
- Exchange
- HNRG Nasdaq
- OLMA Nasdaq
- Market Cap
- HNRG 823.6M
- OLMA 725.5M
- IPO Year
- HNRG N/A
- OLMA 2020
- Fundamental
- Price
- HNRG $19.33
- OLMA $22.85
- Analyst Decision
- HNRG Strong Buy
- OLMA Strong Buy
- Analyst Count
- HNRG 4
- OLMA 6
- Target Price
- HNRG $20.00
- OLMA $30.00
- AVG Volume (30 Days)
- HNRG 549.3K
- OLMA 6.9M
- Earning Date
- HNRG 11-10-2025
- OLMA 11-10-2025
- Dividend Yield
- HNRG N/A
- OLMA N/A
- EPS Growth
- HNRG N/A
- OLMA N/A
- EPS
- HNRG N/A
- OLMA N/A
- Revenue
- HNRG $461,142,000.00
- OLMA N/A
- Revenue This Year
- HNRG $11.19
- OLMA N/A
- Revenue Next Year
- HNRG $4.79
- OLMA N/A
- P/E Ratio
- HNRG N/A
- OLMA N/A
- Revenue Growth
- HNRG 7.15
- OLMA N/A
- 52 Week Low
- HNRG $8.37
- OLMA $2.86
- 52 Week High
- HNRG $24.70
- OLMA $27.17
- Technical
- Relative Strength Index (RSI)
- HNRG 43.66
- OLMA 85.79
- Support Level
- HNRG $19.63
- OLMA $7.82
- Resistance Level
- HNRG $21.80
- OLMA $24.83
- Average True Range (ATR)
- HNRG 1.47
- OLMA 1.98
- MACD
- HNRG -0.24
- OLMA 1.69
- Stochastic Oscillator
- HNRG 5.93
- OLMA 78.39
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.